Cosciens Biopharma provides update on development projects

Pharmaceuticals: Avenanthramides tablets – Anti-inflammatory product: The Single Ascending Dose arm of the Company’s Phase 1 safety and tolerability study has been completed with 48 healthy subjects with no significant clinical adverse events. The Montreal Heart Institute will now enroll 24 additional subjects, each of them receiving specific ascending doses. The Phase 1 study is expected to be completed by year-end. Yeast beta glucan – Anti-fibrotic product: Pre-clinical studies successfully conducted over the last four years with researchers at McMaster University were published on September 9, 2024 in the prestigious publication, Biomaterials Scientific Journal. The data published demonstrated that PGX-processed yeast beta glucan is respirable and able to safely and reliably reprogram cells responsible for the development of fibrotic disease like lung fibrosis in pre-clinical models. AIM Biologicals – Parkinson’s Disease: An abstract related to the Company’s AIM Biologicals PD development program was presented at the European Congress of Immunology held September 1-4, 2024, in Dublin by Dr. Jorg Wischhusen from Wurzburg University as part of the “INNOVATIVE TECHNOLOGIES AND IMMUNOTHERAPIES” track. The goal of this pre-clinical program is to demonstrate that the product confers neuroprotection in an animal model for Parkinson Disease. Nutraceuticals: Yeast beta glucan – Immune booster: Development of a YBG powder formulation for use as an immune booster has been completed. Cosmeceuticals: Avenanthramides and Oat beta glucan – Wound healing: Positive data from a pre-clinical study using AVA and OBG products were presented by Dr. Vince Li, Scientific Director of the Angiogenesis Foundation at the 2024 American Society for Nutrition Annual Meeting held in Chicago at the beginning of July 2024. The pre-clinical data demonstrated that both AVA and OBG accelerate the speed and quality of healing. Technology Development: Pressurized Gas eXpanded Technology: Edmonton Main Facility – PGX Scale-Up 50 Liters Vessel: Construction, installation and commissioning is completed. Validation trials using YBG were successfully performed to produce powder formulation. We plan to sell YBG produced from this facility as a nutraceutical in capsulation form. Austria Natex Facility – PGX Scale-Up 100 Liters Vessel: The project is on schedule.